Vident Advisory, LLC Biogen Inc. Transaction History

Vident Advisory, LLC

$10.5 Trillion
Q3 2025

A detailed history of Vident Advisory, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 4,997 shares of BIIB stock, worth $837,247. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,997

Previous 5,064 1.32%

Holding current value

$837,247

Previous $636 Million 10.06%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$122.68 - $148.84 $8,219 - $9,972	-67 Reduced 1.32%	4,997 $700 Million
Q2 2025 Aug 14, 2025	SELL	$113.38 - $135.49 $200,229 - $239,275	-1,766 Reduced 25.86%	5,064 $636 Million
Q1 2025 May 15, 2025	BUY	$133.43 - $153.27 $726,392 - $834,401	5,444 Added 392.78%	6,830 $935 Million
Q4 2024 Feb 14, 2025	BUY	$146.47 - $191.55 $24,314 - $31,797	166 Added 13.61%	1,386 $212 Million
Q3 2024 Nov 14, 2024	SELL	$189.07 - $236.8 $95,291 - $119,347	-504 Reduced 29.23%	1,220 $237 Million

Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $127,267 - $158,128	-668 Reduced 27.93%	1,724 $400 Million
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $1.41 Million - $1.78 Million	-6,642 Reduced 73.52%	2,392 $516 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $660,869 - $795,513	2,969 Added 48.95%	9,034 $2.34 Billion
Q3 2023 Feb 21, 2024	SELL	$253.3 - $285.89 $752,047 - $848,807	-2,969 Reduced 32.86%	6,065 $1.56 Billion
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $1.54 Million - $1.73 Million	6,065 New	6,065 $1.56 Billion

Others Institutions Holding BIIB

# of Institutions

1,074

Shares Held

131M

Call Options Held

3.77M

Put Options Held

2.31M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $24.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.

Account

Vident Advisory, LLC Biogen Inc. Transaction History